The anti-histone H3 antibody (ab1791) is the most trusted antibody as it can deliver consistent, high-quality results.
The H3 antibody is also the most cited anti-histone antibody. It has been referenced in more than 1,500 research articles, as seen in figure 1.
The antibody offered by Abcam was used recently to help understand the epigenetic regulation of acute myeloid leukemia1 and hormonal gene expression2.
Figure 1. Citations for our anti-histone antibodies each year since 2002 (data from Citeab).
Recommended by Our Customers
In 170 independent product reviews (Abreviews®), customers rate the H3 antibody by Abcam as excellent, as seen in Figure 2.
Figure 2. The total number of customer reviews for our anti-histone H3 antibody (ab1791).
Highly Rated Across Key Applications
When it comes to key applications, such as WB, ChIp, immunoprecipitation, IHC and ICC, Abcam’s H3 antibody (ab1791) is also rated with five stars, as seen in Figure 3.
Figure 3. Star ratings (0–5) for anti-histone H3 antibody (ab1791) given by Abcam’s customers and sorted by application. Numbers in brackets indicates the average rating given for that application.
- Duren RP et al (2016) Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells. PLoS ONE 11(3): e0150450.
- Xi Zhang et al (2016) G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression. Nature Communications 7, Article number: 10810.
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.